Multivariate adjusted odds ratios (95% confidence intervals) for initiating GLP-1 receptor agonists compared with initiators of non-GLP-1RA anti-diabetic drugs in type 2 diabetes patients of primary care in Germany. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.